Navigation Links
Community MRSA is re-emergence of 1950s pandemic, study suggests

An early type of antibiotic-resistant bacteria that caused a global epidemic of infections in the 1950s has re-emerged as one of the community-acquired MRSA 'superbugs', according to a study published in The Lancet tomorrow (Saturday 2 April 2005).

This "re-equipping and re-emergence" of a clone that caused a pandemic 40-50 years ago could mean that community acquired MRSA will spread faster and be more widespread than previously expected, warns an international team of researchers who have been studying the bacteria.

First isolated in Australia and Canada in 1953, type 80/81 penicillin-resistant Staphylococcus aureus bacteria caused skin lesions, sepsis and pneumonia in children and young adults around the world. This pandemic of both hospital and community acquired infections waned throughout the 1960s as the antibiotic meticillin was used to treat these infections.

Now researchers have shown that one of the key clones of community acquired MRSA (CA-MRSA) - infections picked up in public places which are resistant to treatment by powerful meticillin antibiotics - may have evolved from this earlier pandemic-causing strain.

The researchers have sequenced key genes from 80/81 samples isolated between 1955 and 1969 in Australia, England and the USA, and compared them with the same regions in genes from a clone of one of the most common CA MRSAs which has been found in England and Scotland.

They found that these key regions in nearly all of the 80/81 isolates were identical to the CA-MRSA clone, and also that they share the same highly-virulent toxin, called Panton-Valentine leucocidin.

They believe that their findings suggest that this particular CA MRSA clone has evolved from the earlier 80/81 type, developing resistance to meticillin antibiotics over the last 30-40 years, possibly through several intermediate steps.

"At the time of the 1950s pandemic, many doctors thought that these isolates were unusually trans missible and virulent," said Dr Mark Enright from Department of Biology and Biochemistry the University of Bath (UK) who is leading the research.

"We have shown that 80/81 and its souped-up community acquired MRSA descendent share many of the same features, which explains why 1950s pandemic was so successful, but also shows why community acquired MRSA could pose such a serious public health challenge in coming years.

"The community acquired MRSA clone has a toxin and other traits with a proven track record for causing serious diseases in healthier and younger age groups than those currently regarded as at risk. The increased resistance to antibiotics of the community acquired MRSA clone over its 80/81 ancestor mean that there could also be other factors which complicate the treatment of the disease it causes."


'"/>

Source:University of Bath


Related biology news :

1. Bioartificial kidney under study at MCG
2. W.M. Keck Foundation funds study of friendly microbes
3. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
4. Genome-wide mouse study yields link to human leukemia
5. Clam embryo study shows pollutant mixture adversely affects nerve cell development
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Same mutation aided evolution in many fish species, Stanford study finds
8. Sequencing of marine bacterium will help study of cell communication
9. Genetically modified rice in China benefits farmers health, study finds
10. A new study examines how shared pathogens affect host populations
11. NYU study reveals how brains immune system fights viral encephalitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a ... with the release of its patent-pending calibration device. With ... reliably perform calibrations, securely upload data logs and process ... the customer. "Fighting drunk driving through the ... the public at large, but also for the customer ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
(Date:1/6/2017)... 2017  Delta ID Inc., a leader in consumer-grade ... automotive at CESĀ® 2017. Delta ID has collaborated with ... the use of iris scanning as a secure, reliable ... in a car, and as a way to elevate ... Delta ID and Gentex will demonstrate (booth #7326 ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... , Jan. 20, 2017 Bioptix, Inc. ... "Company"), announced that on January 14, 2017 the Board ... which the Company will terminate certain employees associated with ... Inc.  The Company commenced terminations on January 16, 2017 ... days.  The Company may pay severance benefits in certain ...
(Date:1/20/2017)... -- Ginkgo Bioworks, the organism company, announced today ... synthesis and assembly of DNA. The acquisition will ... DNA into Ginkgo,s automated organism engineering foundries, enabling ... new organism designs for application across a wide ... to significantly increase the world,s capacity to cost-effectively ...
(Date:1/19/2017)... LOUISVILLE, Ky. and HOUSTON ... Prenatal Inc. ("NX Prenatal") today announced the formation ... brings together leading clinicians and industry veterans who ... the company as it accelerates development of its ... positioned to provide medical, clinical and strategic guidance ...
(Date:1/19/2017)... Md. and GAITHERSBURG, Md. ... (NYSE MKT: PIP) and Altimmune, Inc., a privately-held ... signing of a definitive agreement for the merger ... Altimmune,s current investors include Novartis Venture Fund, HealthCap, ... will be a fully-integrated and diversified immunotherapeutics company ...
Breaking Biology Technology: